Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on October 30, 2013, with a report date of March 6, 2014. The filing discloses the entry into a Material Definitive Agreement regarding a technology license.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial obligations disclosed include:
- Payment Made: $1.0 million paid to Austrianova Singapore Pte. Ltd. on October 30, 2013.
- Future Obligation (at time of filing): A second payment of $1.0 million was due by April 30, 2014.
- Subsequent Event: The second payment of $1.0 million was made on February 25, 2014, fulfilling all financial obligations under the agreement.
Material Changes
The primary material change is the execution of a Licensing Agreement effective June 25, 2013, with Austrianova Singapore Pte. Ltd. This agreement granted Nuvilex an exclusive, worldwide license to use the "Cell-in-a-Box" cellulose-based live-cell encapsulation technology and trademark for the treatment of diabetes.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the licensing terms and payment schedule. The filing notes that the second payment was a condition to retain the exclusive worldwide license for diabetes treatment development. No specific risks, contingencies, or forward-looking guidance regarding product development timelines or market expectations are detailed in this text.
Investor Verification Checklist
- Verify the total cash outflow of $2.0 million paid to Austrianova Singapore Pte. Ltd.
- Confirm the status of the "Cell-in-a-Box" technology development for diabetes treatment.
- Review the company's liquidity position to ensure it can support ongoing R&D following the $2.0 million expenditure.
- Check for any subsequent filings regarding the commercialization progress of the licensed technology.